BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 14750175)

  • 1. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single nucleotide polymorphisms modify the transporter activity of ABCG2.
    Morisaki K; Robey RW; Ozvegy-Laczka C; Honjo Y; Polgar O; Steadman K; Sarkadi B; Bates SE
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):161-72. PubMed ID: 15838659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
    Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
    Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of SNPs variants of BCRP/ABCG2.
    Kondo C; Suzuki H; Itoda M; Ozawa S; Sawada J; Kobayashi D; Ieiri I; Mine K; Ohtsubo K; Sugiyama Y
    Pharm Res; 2004 Oct; 21(10):1895-903. PubMed ID: 15553238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
    Kim IS; Kim HG; Kim DC; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Lee GW
    Cancer Sci; 2008 Dec; 99(12):2496-501. PubMed ID: 19032367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
    Tamura A; Wakabayashi K; Onishi Y; Takeda M; Ikegami Y; Sawada S; Tsuji M; Matsuda Y; Ishikawa T
    Cancer Sci; 2007 Feb; 98(2):231-9. PubMed ID: 17297656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
    Henriksen U; Gether U; Litman T
    J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).
    Honjo Y; Morisaki K; Huff LM; Robey RW; Hung J; Dean M; Bates SE
    Cancer Biol Ther; 2002; 1(6):696-702. PubMed ID: 12642696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
    Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T
    Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
    Ozvegy C; Litman T; Szakács G; Nagy Z; Bates S; Váradi A; Sarkadi B
    Biochem Biophys Res Commun; 2001 Jul; 285(1):111-7. PubMed ID: 11437380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.
    Pál A; Méhn D; Molnár E; Gedey S; Mészáros P; Nagy T; Glavinas H; Janáky T; von Richter O; Báthori G; Szente L; Krajcsi P
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1085-94. PubMed ID: 17347325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein.
    Sarankó H; Tordai H; Telbisz Á; Özvegy-Laczka C; Erdős G; Sarkadi B; Hegedűs T
    Biochem Biophys Res Commun; 2013 Jul; 437(1):140-5. PubMed ID: 23800412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
    Ripperger A; Benndorf RA
    Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
    Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
    Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).
    Robey RW; Honjo Y; van de Laar A; Miyake K; Regis JT; Litman T; Bates SE
    Biochim Biophys Acta; 2001 Jun; 1512(2):171-82. PubMed ID: 11406094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
    Furukawa T; Wakabayashi K; Tamura A; Nakagawa H; Morishima Y; Osawa Y; Ishikawa T
    Pharm Res; 2009 Feb; 26(2):469-79. PubMed ID: 18958403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N.
    Vethanayagam RR; Wang H; Gupta A; Zhang Y; Lewis F; Unadkat JD; Mao Q
    Drug Metab Dispos; 2005 Jun; 33(6):697-705. PubMed ID: 15743976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.